InfuSystem (NYSE:INFU) Now Covered by Analysts at Lake Street Capital

Key Points

• Lake Street Capital has initiated coverage on InfuSystem with a "buy" rating and a price target of $15.00, indicating a potential upside of 49.11% from its previous close.
• Roth Capital also began coverage, setting a "buy" rating with a price target of $12.00, contributing to an average target price of $13.33 based on multiple analysts' ratings.
• InfuSystem's shares traded at $10.06 recently, showing a 12-month low of $4.61 and a high of $11.04, while approximately 71.13% of the stock is currently owned by institutional investors.

Investment analysts at Lake Street Capital began coverage on shares of InfuSystem (NYSE:INFU - Get Free Report) in a report released on Monday, MarketBeat reports. The brokerage set a "buy" rating and a $15.00 price target on the stock. Lake Street Capital's price objective indicates a potential upside of 44.09% from the company's current price.

Separately, Roth Capital started coverage on shares of InfuSystem in a research report on Tuesday, July 22nd. They set a "buy" rating and a $12.00 target price on the stock. Three analysts have rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Strong Buy" and a consensus price target of $13.33.

InfuSystem Price Performance

NYSE:INFU traded up $0.41 during trading hours on Monday, reaching $10.41. The stock had a trading volume of 420,443 shares, compared to its average volume of 183,676. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.59 and a current ratio of 1.98. The stock has a market capitalization of $212.63 million, a PE ratio of 173.53 and a beta of 1.82. InfuSystem has a 52 week low of $4.61 and a 52 week high of $11.04. The company has a 50 day moving average price of $8.51 and a two-hundred day moving average price of $6.62.

Insider Activity

In other news, Director Scott Shuda sold 5,752 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $9.67, for a total transaction of $55,621.84. Following the transaction, the director owned 94,000 shares of the company's stock, valued at approximately $908,980. This represents a 5.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 11.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On InfuSystem

Several hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets raised its stake in InfuSystem by 67.9% in the fourth quarter. BNP Paribas Financial Markets now owns 6,844 shares of the company's stock worth $58,000 after buying an additional 2,768 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of InfuSystem by 19.4% in the 2nd quarter. Bank of America Corp DE now owns 17,994 shares of the company's stock valued at $112,000 after acquiring an additional 2,924 shares during the period. Bank of New York Mellon Corp raised its position in shares of InfuSystem by 4.7% in the 1st quarter. Bank of New York Mellon Corp now owns 95,471 shares of the company's stock worth $514,000 after acquiring an additional 4,252 shares in the last quarter. CWM LLC lifted its stake in shares of InfuSystem by 1,160.1% during the 2nd quarter. CWM LLC now owns 4,826 shares of the company's stock worth $30,000 after purchasing an additional 4,443 shares during the last quarter. Finally, Millennium Management LLC boosted its position in InfuSystem by 6.3% during the fourth quarter. Millennium Management LLC now owns 76,419 shares of the company's stock valued at $646,000 after purchasing an additional 4,532 shares in the last quarter. Institutional investors own 71.13% of the company's stock.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.